N
Nathan P. Englund
Researcher at Genomics Institute of the Novartis Research Foundation
Publications - 6
Citations - 994
Nathan P. Englund is an academic researcher from Genomics Institute of the Novartis Research Foundation. The author has contributed to research in topics: Smoothened & Smoothened Receptor. The author has an hindex of 6, co-authored 6 publications receiving 904 citations. Previous affiliations of Nathan P. Englund include Novartis.
Papers
More filters
Journal ArticleDOI
Essential role of stromally induced hedgehog signaling in B-cell malignancies
Christine Dierks,Christine Dierks,Jovana Grbic,Katja Zirlik,Ronak Beigi,Nathan P. Englund,Gui-Rong Guo,Hendrik Veelken,Monika Engelhardt,Roland Mertelsmann,Joseph Kelleher,Peter G. Schultz,Peter G. Schultz,Markus Warmuth +13 more
TL;DR: It is demonstrated that hedgehog ligands secreted by bone-marrow, nodal and splenic stromal cells function as survival factors for malignant lymphoma and plasmacytoma cells derived from transgenic Eμ-Myc mice or isolated from humans with these malignancies.
Journal ArticleDOI
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
Shifeng Pan,Xu Wu,Jiqing Jiang,Wenqi Gao,Yongqin Wan,Dai Cheng,Dong Han,Jun Liu,Nathan P. Englund,Yan Wang,Stefan Peukert,Karen Miller-Moslin,Jing Yuan,Ribo Guo,Melissa Matsumoto,Anthony Vattay,Yun Jiang,Jeffrey Tsao,Fangxian Sun,AnneMarie Culazzo Pferdekamper,Stephanie Kay Dodd,Tove Tuntland,Wieslawa Maniara,Joseph Kelleher,Yung-mae Yao,Markus Warmuth,Juliet Williams,Marion Dorsch +27 more
TL;DR: Structural-activity relationship studies led to the discovery of a potent and specific Smoothened antagonist N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl- 3-carboxamide (5m, NVP-LDE225), which is currently in clinical development.
Journal ArticleDOI
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia
Jacob D. Jaffe,Yan Wang,Ho Man Chan,Jinghui Zhang,Robert Huether,Gregory V. Kryukov,Gregory V. Kryukov,Gregory V. Kryukov,Hyo-eun C. Bhang,Jordan E. Taylor,Min Hu,Nathan P. Englund,Feng Yan,Zhaofu Wang,E. Robert McDonald,Lei Wei,Jing Ma,John Easton,Zhengtian Yu,Rosalie deBeaumount,Veronica Gibaja,Kavitha Venkatesan,Robert Schlegel,William R. Sellers,Nicholas Keen,Jun Liu,Giordano Caponigro,Jordi Barretina,Vesselina G. Cooke,Charles G. Mullighan,Steven A. Carr,James R. Downing,Levi A. Garraway,Levi A. Garraway,Frank Stegmeier +34 more
TL;DR: In this article, a high-information-content mass spectrometry approach was developed to profile global histone modifications in human cancers. When applied to 115 lines from the Cancer Cell Line Encyclopedia1, this approach identified distinct molecular chromatin signatures.
Journal ArticleDOI
NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma
Zheng Huang,Haiping Wu,Shannon Chuai,Fiona Xu,Feng Yan,Nathan P. Englund,Zhaofu Wang,Hailong Zhang,Ming Fang,Youzhen Wang,Justin Gu,Man Zhang,Teddy Yang,Kehao Zhao,Yanyan Yu,Jingquan Dai,Wei Yi,Shaolian Zhou,Qian Li,Jing Wu,Jun Liu,Xu Wu,Ho Man Chan,Chris Lu,Peter Atadja,En Li,Yan Wang,Min Hu +27 more
TL;DR: It is shown that N SD2 methyltransferase activity is crucial for clonogenicity, adherence, and proliferation of multiple myeloma cells on bone marrow stroma in vitro and that NSD2 is required for tumorigenesis of t(4;14)+ but not t( 4;14)- multiple myELoma cells in vivo.
Journal ArticleDOI
Small Molecule Antagonists in Distinct Binding Modes Inhibit Drug-Resistant Mutant of Smoothened
Haiyan Tao,Qihui Jin,Dong-In Koo,Xuebin Liao,Nathan P. Englund,Yan Wang,Arun Ramamurthy,Peter G. Schultz,Marion Dorsch,Joseph Kelleher,Xu Wu,Xu Wu +11 more
TL;DR: These findings provide an insight of the ligand-binding sites of Smo and a basis for the development of potential therapeutics for tumors with drug-resistant Smo mutations.